We source APIs from manufacturers in China and India, and we assess them the way a formulator would: impurity profile, polymorphic form, particle size and the regulatory file behind them.
NJMC Medical Supplies sources active pharmaceutical ingredients from manufacturers in China and India for buyers in China, Yemen, the Middle East and the United Kingdom. APIs are assessed on impurity profile, polymorphic form, particle size distribution and regulatory documentation before price is discussed. NJMC is a sourcing and consultancy company, not a manufacturer.
Most API sourcing goes wrong for one of two reasons. Either the material is not what the paperwork claims, or the paperwork itself will not survive contact with the regulator in the importing country. Both are avoidable, and avoiding them is technical work rather than commercial work.
That is the distinction this business is built on. A trading desk compares offers. We read the certificate of analysis against the specification, ask which site actually manufactured the batch, and check whether the regulatory file supports the filing you intend to make.
Price is the last question, not the first. Before that:
What you need depends on where you are filing. We establish that before shortlisting, because retrofitting a document package after an order is placed is rarely possible.
| Document | What it does for you |
|---|---|
| Certificate of Analysis | Batch specific results against the agreed specification. Ask for the batch, not a specimen. |
| GMP certificate | Confirms the manufacturing site operates under a recognised quality system. Check the site address and the expiry. |
| Drug Master File | Supports a filing without exposing the manufacturer's confidential process to you. |
| CEP, where it exists | Certificate of suitability to the European Pharmacopoeia. Strong evidence, and easy to verify independently. |
| Stability data | Supports shelf life and storage claims, and is often the gap in a package that otherwise looks complete. |
Sourcing is done to your specification rather than from a fixed catalogue, which means the practical limit is what can be manufactured to standard and documented properly, not what happens to be in stock.
A note on what NJMC is. We are a sourcing and consultancy company, not a manufacturer. We do not own production facilities and we do not represent a single factory. That independence is the point: it means a shortlist reflects what fits your specification rather than what we hold.
We work with buyers in China, Yemen, the wider Middle East and the United Kingdom. Requirements differ by market, and a certificate that satisfies one regulator will not always satisfy another.
No. NJMC is a sourcing and consultancy company. We do not own production facilities and we do not represent a single factory, which is what allows a shortlist to reflect your specification rather than our inventory.
Depending on the manufacturer and your filing route, this can include a batch specific certificate of analysis, the GMP certificate for the manufacturing site, a Drug Master File with letter of access, a CEP where one exists, and stability data. We establish what your destination market requires before shortlisting.
A different polymorph can be chemically identical and pharmaceutically unusable, because solubility and dissolution behaviour change. The form has to be stated on the specification and controlled by the manufacturer, not assumed.
China, Yemen, the wider Middle East and the United Kingdom. Requirements differ by market and a certificate accepted by one regulator will not always satisfy another.
Send the product or molecule, the grade, the quantity and the destination market. You will get a considered answer about what can be sourced and what documentation comes with it.